Skip to main content

Table 7 Safety outcomes: OHSS

From: In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review

Characteristic Total rFSH hMG-hp Chi-square p-value
Number of cycles started* 28063 20144 7919   
Cycles with OHSS (Severity I, II, III and hospitalisation) 4928 (17.56%) 3812 (18.92%) 1116 (14.09%) 91.64 <0.0001
-Hospitalisation due to OHSS as percent of cycles with OHSS 268 (5.44%) 215 (5.64% of cycles with OHSS) 53 (4.75% of cycles with OHSS) 1.33 0.2483
-Hospitalisation due to OHSS as percent of cycles started 268 (0.95%) 215 (1.07% of cycles started) 53 (0.67% of cycles started) 9.52 0.002
  1. *Due to lack of data on this outcome only data from Germany were included